Since immunotherapy with anti-PD-1 antibody targets PD-1/PD-L1 immune checkpoint blockade, the expression levels of related molecules such as the PD-L1 on tumor cells have attracted a great deal of attention for predicting response and efficacy to the treatment5,30–32. The gene discussed is PDCD1; the disease is neoplasm.